A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
Zacks Investment Research on MSN1d
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE DrugsNovartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
GlobalData on MSN2d
Royalty Pharma pays $250m for rights to Biogen’s lupus drugRoyalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.
Recently, a letter to the editor I wrote was published in the Arkansas Democrat-Gazette on the subject of skyrocketing health-care costs, inclusive of rising pharmaceutical drug prices. I referenced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback